The FDA’s Priority Review designation allows for a shortened review period (within 6 months) from the time of application acceptance.
The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...
GLP-1 RA use with subsequent prepregnancy or early pregnancy discontinuation linked to higher risk for preterm delivery, gestational diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback